The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients - A pharmacokinetic model

Health Physics

Volumn 91, Issue 3, 2006, Pages 227-237

  Pahlka, Raymond B ^b   Sonnad, Jagadeesh R ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

Cancer; Dose assessment; Radiation, medical; Thyroid

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ARTICLE; BLADDER; BLOOD; BONE MARROW; COMPARTMENT MODEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DATA ANALYSIS SOFTWARE; DOSIMETRY; DRUG ELIMINATION; GASTROINTESTINAL TRACT; HEMODIALYSIS; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION; KINETICS; MATHEMATICAL ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION ABSORPTION; THYROID CARCINOMA; THYROID GLAND; VALIDITY; BIOLOGICAL MODEL; CHRONIC KIDNEY FAILURE; COMPUTER PROGRAM; HUMAN; METABOLISM; RADIATION DOSE; RADIATION EXPOSURE; RENAL REPLACEMENT THERAPY; THYROID TUMOR;

BONE MARROW; HUMANS; IODINE RADIOISOTOPES; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; RADIOTHERAPY DOSAGE; RENAL DIALYSIS; SOFTWARE; THYROID GLAND; THYROID NEOPLASMS;

EID: 33746881000     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HP.0000214660.13440.64     Document Type: Article

References (40)

1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol 87:171-182; 1962.
2. Berman M, Weiss MF, Shahn E. Some formal approaches to the analysis of kinetic data in terms of linear compartmental systems. Biophysical J 2:289-316; 1962.
3. Berman M, Hoff E, Barandes M, Becker DV, Sonenberg M, Benua R, Koutras DA. Iodine kinetics in man - a model. J Clinical Endocrinol Metabolism 28:1-14; 1968.
4. Berman M, Braverman LE, Burke J, de Groot L, McCormack KR, Oddie TH, Rohrer RH, Wellman HN, Smith EM. MIRD/Dose estimate report No. 5: Summary of current radiation dose estimates to humans from I-123, I-124, I-125, I-126, I-127, I-130, I-131, and I-132 as sodium iodide. J Nucl Med 16:857-860; 1975.
5. Brownell GL. Analysis of techniques for the determination of thyroid function with radioiodine. J Clinical Endocrinol Metabolism 11:1095-1105; 1951.
6. Culpepper RM, Hirsch JI, Fratkin MJ. Clearance of I-131 by hemodialysis. Clin Nephrol 38:110-114; 1992.
7. Curti G, DeMartini D, Santaniello B, Taddel G, Fresco GF. A theoretical four-compartment model to evaluate separate kidney technetium-99m-MAG3 kinetics in humans. Kidney International 54:2029-2036; 1998.
8. Daumerie C, Vynckier S, Caussin J, Jadoul M, Squifflet JP, de Patoul N, Wambersie A. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid 6:301-304; 1996.
9. Eckerman KF. Dosimetric methodology of the ICRP. In: Rabbe OG, ed. Internal radiation dosimetry. Madison, WI: Medical Physics Publishing; 1994: 239-270.
10. Hamby DM, Benke RR. Uncertainty of the iodine-131 ingestion dose conversion factor. Radiat Protect Dosim 82:245-256; 1999.
11. Harvey RP, Hamby DM, Benke RP. Age-specific uncertainty of the iodine-131 ingestion dose conversion factor. Health Phys 84:334-343; 2003.
12. Homer I, Smith AH. Radiation protection issues of treating hyperthyroidism with I-131 in patients on haemodialysis. Nucl Med Comm 23:261-264; 2002.
13. Howard N, Glasser M. Iodine 131 ablation therapy for a patient on maintenance haemodialysis. Br J Radiol 54:259; 1981.
14. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. Oxford: Pergamon Press; ICRP Publication 30; 1979.
15. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon Press; ICRP Publication 53; 1987.
16. International Commission on Radiological Protection. Age-dependent doses to members of the public from intake of radionuclides: part 1. Oxford: Pergamon Press; ICRP Publication 56; 1989.
17. Jimenez RG, Moreno AS, Gonzalez EN, Simon FJL, Rodriguez JRR, Jimenez JC, Cordoba MH, Albertino RV, Jimenez RA. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method. Thyroid 11:1031-1034; 1998.
18. Kaptein EM. Thyroid function in renal failure. Contributions in Nephrol 50:64-72; 1986.
19. Kaptein EM, Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriquez HJ, Massry SG. The thyroid in end-stage renal disease. Med 67:187-197; 1988.
20. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clinical Endocrinol Metabolism 85:3058-3064; 2000.
21. Keating FR, Power MH, Berkson J, Haines SF. The urinary excretion of radioiodine in various thyroid states. J Clinical Investigation 26:1138-1151; 1947.
22. Keating FR, Wang JC, Luellen TJ, Williams MMD, Power MH, McConahey WM. The measurement of the iodine-accumulating function of the human thyroid gland. J Clinical Investigation 28:217-227; 1949.
23. Leggett RW, Williams LR. A proposed blood circulation model for reference man. Health Phys 69:187-201; 1995.
24. Luellen TJ, Keating FR, Williams MMD, Berkson J, Power MH, McConahey WM. Relative measurement in vivo of accumulation of radioiodine by the human thyroid gland: comparison with radioactivity in peripheral tissues. J Clinical Investigation 28:207-216; 1949.
25. Magne N, Magne J, Bracco J, Bussiere F. Disposition of radioiodine I-131 therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis: a case report. Jpn J Clin Oncol 32:202-205; 2002.
26. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New England J Med 309:937-941; 1983.
27. Meller J, Sahlmann CO, Becker W. Nuclear medicine studies in the dialysis patient. Seminars in Dialysis 15:269-276; 2002.
28. Mello AM, Isaacs R, Petersen J, Kronenberger S, McDougall R. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clinical Nucl Med 19:776-781; 1994.
29. Morrish DW, Filipow LJ, McEwan AJ, Schmidt R, Murland DR, Von Westarp C, Betcher KB. 131-I treatment of thyroid papillary carcinoma in a patient with renal failure. Cancer 66:2569-2573; 1990.
30. Oddie TH, Flanigan WJ, Fisher DA. Iodine and thyroxine metabolism in anephric patients receiving chronic peritoneal dialysis. J Clinical Endocrinol Metabolism 31:277-282; 1970.
31. Papanastassiou V, Pizer BL, Chandler CL, Zananiri TF, Kemshead JT, Hopkins KI. Pharmacokinetics and dose estimates following intrathecal administration of I-131 monoclonal antibodies for the treatment of central nervous system malignancies. International J Radiat Oncol Biol Phys 31:541-552; 1995.
32. Perry WF, Hughes JFS. The urinary excretion and thyroid uptake of iodine in renal disease. J Clinical Investigation 31:457-463; 1952.
33. Riggs DS. Quantitative aspects of iodine metabolism in man. Pharmacological Review 4:284-370; 1952.
34. Schneditz D, Daugirdas JT. Compartment effects in hemodialysis. Seminars in Dialysis 14:271-277; 2001.
35. Shinaberger JH. Quantitation of dialysis: historical perspective. Seminars in Dialysis 14:238-245; 2001.
36. Singh B, Sharma SM, Patel MC, Raghavendran KV, Berman M. Kinetics of large therapy doses of iodine-131 in patients with thyroid cancer. J Nucl Med 15:674-678; 1974.
37. Snyder WS, Ford MR, Warner GG, Watson SB. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. Reston, VA: Society of Nuclear Medicine; NM/MIRD Pamphlet No. 11; 1975.
38. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538-546; 1996.
39. Toubert ME, Michel C, Metivier F, Peker MC, Rain JD. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis. Clinical Nucl Med 26:302-305; 2001.
40. Vetter RJ. Medical health physics: a review. Health Phys 86:445-456; 2004.